APA (7th ed.) Citation

Matulonis, U. A., Lorusso, D., Oaknin, A., Pignata, S., Dean, A., Denys, H., . . . Coleman, R. L. (2023). Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. Journal of clinical oncology, 41(13), 2436-2445. https://doi.org/10.1200/JCO.22.01900

Chicago Style (17th ed.) Citation

Matulonis, Ursula A., et al. "Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study." Journal of Clinical Oncology 41, no. 13 (2023): 2436-2445. https://doi.org/10.1200/JCO.22.01900.

MLA (9th ed.) Citation

Matulonis, Ursula A., et al. "Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study." Journal of Clinical Oncology, vol. 41, no. 13, 2023, pp. 2436-2445, https://doi.org/10.1200/JCO.22.01900.